Novartis’ Reclast Gains Paget’s Approval, But Still Waiting On Osteoporosis

Novartis' Paget's disease treatment Reclast (zoledronic acid) will launch with an apparent pricing advantage over the current standard of care, Proctor & Gamble's Actonel (risedronate)